Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue Donors.

JAMA neurology·2026
Same author

At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial.

Muscle & nerve·2026
Same author

Optimizing Research Operations and Resource Utilization in ALS Care: Insights From the Tofersen Antisense Oligonucleotide Expanded Access Protocol.

Muscle & nerve·2026
Same author

Bridging the Funding Gap in Drug Development for Amyotrophic Lateral Sclerosis.

Neurology. Clinical practice·2026
Same author

Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neurofilament Analyses.

Muscle & nerve·2026
Same author

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

JAMA neurology·2026

Related Experiment Video

Updated: Nov 17, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

20.3K

Measuring disease progression in primary lateral sclerosis.

Madison Gilmore1, Lauren Elman2, Suma Babu3

  • 1Department of Neurology, Columbia University Medical Center, New York, NY, USA.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|February 19, 2021
PubMed
Summary

Accurate outcome measures are vital for primary lateral sclerosis (PLS) clinical trials. The PLS Functional Rating Scale (PLSFRS) shows promise for tracking disease progression effectively over time.

Keywords:
Primary lateral sclerosisdisease progressionoutcome measures

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.4K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.3K

Related Experiment Videos

Last Updated: Nov 17, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

20.3K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.4K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.3K

Area of Science:

  • Neurology
  • Clinical Trials
  • Outcome Measurement

Background:

  • Quantitative disease severity measures are crucial for clinical trials.
  • Primary Lateral Sclerosis (PLS) exhibits slow progression, necessitating sensitive clinical outcome measures.
  • Existing measures need evaluation for their ability to detect changes within trial timelines.

Purpose of the Study:

  • To review proposed clinical outcome measures for Primary Lateral Sclerosis (PLS).
  • To assess the reliability and longitudinal sensitivity of different measures.
  • To identify the most suitable measures for tracking disease progression in PLS clinical trials.

Main Methods:

  • Review of proposed clinical outcome measures for PLS.
  • Evaluation of the Primary Lateral Sclerosis Functional Rating Scale (PLSFRS) for reliability and change over time.
  • Assessment of Upper Motor Neuron Burden (UMNB) scales.
  • Consideration of quantitative motor performance measures (strength, dexterity, gait, speech).

Main Results:

  • The PLSFRS demonstrated good inter-rater reliability.
  • PLSFRS showed greater longitudinal change over 6- and 12-month periods compared to the revised ALS Functional Rating Scale.
  • Examination-based UMNB scales possess good reliability, with ongoing longitudinal studies.
  • Quantitative motor performance measures are least studied in PLS but offer potential for objective assessment.

Conclusions:

  • The PLSFRS is a reliable and sensitive measure for assessing disease progression in PLS.
  • UMNB scales are reliable and require further longitudinal validation.
  • Quantitative motor performance measures hold potential for objective assessment but require further research in PLS.